TY  - JOUR
AU  - BAGOT, Jean-Lionel
PY  - 2022
DA  - 2022/07/11
TI  - Improving Tolerance and Compliance of New Targeted Therapies with Homeopathy: A Major Challenge in Oncology
JO  - OBM Integrative and Complementary Medicine
SP  - 026
VL  - 07
IS  - 03
AB  - The application of targeted therapies (TT) in oncology has prolonged survivals and even enabled complete remission of cancers previously considered incurable. With small therapeutic indices, the reduction in dosage or spacing out of the doses of TT due to side effects, represents a significant loss of treatment opportunity for the patients. In the absence of drug interaction and significant side effects, homeopathy used in supportive care improves the quality of life of patients, compliance with oncological treatments and consequently their survival. Based on the author’s clinical experience and published studies, a therapeutic regimen for systematic supportive care of TT is proposed in this study. The originality of the treatment lies in combining a symptomatic diluted and dynamised homeopathic medicine with the patient’s constitutional homeopathic medicine as well as the isotherapeutic agent used for targeted therapy in 7c (10-14). If needs be, the eponymous organotherapy of the organ most affected by the side effects can be added in 4c (10-8). This therapeutic regimen is well accepted and well tolerated. It has been prescribed to approximately 5,000 patients over 25 years including those patients who were given hormone therapy. Facilitating tolerance and acceptance of targeted therapies is very important in oncology in order to fully benefit from the TT efficacy. Homeopathy, organotherapy and isotherapy, by supporting the whole body and treating the major side effects, might improve observance and consequently therapeutic results. Clinical trials could be carried out following the designs and protocols presented in this article.
SN  - 2573-4393
UR  - https://doi.org/10.21926/obm.icm.2203026
DO  - 10.21926/obm.icm.2203026
ID  - BAGOT2022
ER  -